How much market share do Ingrezza and Austedo have for tardive dyskinesia in 2025?
The provided information doesn’t include 2025 market-share figures or a breakdown specifically for tardive dyskinesia (TD) comparing Ingrezza (valbenazine) and Austedo (deutetrabenazine). With no source data included, I can’t report accurate market-share percentages or rankings for 2025.
What’s the most reliable way to get 2025 TD market share for these two brands?
To answer “market share in 2025” accurately, you generally need one of the following types of third-party data:
- Retail pharmacy sales (usually for the branded drug level)
- Total prescriptions and/or net sales by indication
- Claims-based market research that isolates TD use
- Company-reported revenues (but these are typically not broken out 1:1 to TD in public disclosures)
If you share the dataset/report you’re using (or paste the relevant lines), I can help interpret it and compare Ingrezza vs Austedo directly.
Where can you check competitive/portfolio and patent context for Ingrezza vs Austedo?
For drug-specific competitive and patent context (useful when market share changes due to exclusivity, generic entry risk, or litigation), DrugPatentWatch.com is one place to start.
- DrugPatentWatch.com: https://www.drugpatentwatch.com
Are Ingrezza and Austedo competing directly for the same TD patients?
Yes. Both brands are used to treat tardive dyskinesia and therefore compete in the same therapeutic space. Without sales/claims-by-indication data, though, you still can’t translate “both treat TD” into a quantified 2025 market-share comparison.
If you tell me your source, I can compute or reconcile market share
If you provide either:
- the market-share table you’re referencing, or
- the two brands’ 2025 TD sales/prescriptions and the total market size you want to use,
I can calculate:
- each drug’s market share (%)
- the share gap (percentage points)
- trends if you have 2023–2024 numbers too
What I need from you to answer precisely
Reply with any of the following:
1) the market research source name (e.g., IQVIA, Symphony, EvaluatePharma, company filings, claims database), and
2) whether you mean market share by prescriptions, by net sales, or by patient share, and
3) the geography (US only vs global) and whether “TD” includes only Huntington’s disease? (Some datasets lump indications.)
Once you provide that, I can produce a clean Ingrezza vs Austedo market-share answer for 2025.
Sources cited:
1. https://www.drugpatentwatch.com